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Hepatoid carcinoma is a primary extrahepatic carcino-
ma whose morphology, immunohistochemistry, and be-
havior are similar to those of hepatocellular carci-
noma. The most common sites of extrahepatic carci-
noma are the stomach and ovary, but nine cases of 
hepatocellular differentiation of the pancreas have 
been reported in the literature. We report another 
case of hepatoid carcinoma of the pancreas that was 
associated with the development of a pancreatic en-
docrine carcinoma in a 46-year-old man. Serum al-
pha-fetoprotein (AFP) was elevated to 262.49 IU/mL 
and radiological examinations revealed a mass meas-
uring 7.5 cm in diameter in the head of the pancreas. 
He underwent a conventional Whipple operation, and 
light microscopy showed adenocarcinoma that was im-
munopositive for AFP, hepatocyte antigen, cytokeratin, 
chromogranin, synaptophysin, and alpha-1 antichy-
motrypsin. Although hepatoid differentiation was not 
shown unequivocally histologically, other immunohis-
tochemistry findings supported the diagnosis of hep-
atoid carcinoma combined with neuroendocrine car-
cinoma. The patient was healthy and had no evidence 
of recurrence at 4 months after the surgery. This re-
port describes why hepatoid carcinoma should be 
considered as a differential diagnosis of a pancreatic 
mass, especially when serum AFP is elevated. (Gut 
Liver 2010;4:98-102)
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INTRODUCTION
  Hepatoid carcinoma is a type of extrahepatic carcinoma 
that shows a strikingly similar morphology to hep-
atocellular carcinoma (HCC) with alpha-fetoprotein (AFP) 
production, positive immunohistochemistry staining of 
several liver-synthesized proteins, presence of positive pe-
riodic acid-Schiff (PAS), diastase-resistant intracytoplas-
mic globules, bile production, and recently, the more spe-
cific and sensitive in situ hybridization detection of albu-
min messenger RNA (mRNA).1-3 Since Ishikura et al.1 re-
ported a HCC-like differentiation in a primary gastric tu-
mor in 1985, cases of hepatoid carcinoma of the esoph-
agus, papilla of Vater, colon, lung, gallbladder, adrenal 
gland, kidney, urinary bladder, ovary, uterus, vagina, and 
testicle have been documented.2 We report a case of AFP 
producing hepatoid carcinoma combined with poorly dif-
ferentiated neuroendocrine carcinoma arising from the 
pancreas.
CASE REPORT
  A 46-year-old man was referred from a local clinic to 
our hospital because of dyspepsia and pancreatic head 
mass. He had complained of dyspepsia for 1 week and 
visited a local clinic, where an abdominal computed to-
mography (CT) scan was taken. He was neither a habitual 
drinker nor smoker and did not have any specific person-
al or family history of other diseases.
  Physical examinations on admission were unremarkable, 
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Fig. 1. Imaging studies of the 
patients. (A) Pancreas computed 
tomography and (B) pancreatico-
biliary magnetic resonance imag-
ing showed possibility of sub-
mucosal tumor arising from dis-
tal gastric antrum and greater 
curvature side with possible 
adhesion to the pancreas. (C) 
Esophagogastroduodenoscopy 
showed extrinsic compression of 
gastric antrum and duodenum 
second portion. (D) Positron 
emission tomography showed 
abnormal uptake only in duo-
denum or pancreatic head sug-
gesting malignancy.
except for a palpable mass around the epigastric area of 
about 7 cm. Laboratory tests showed normal serum levels 
of carcinoembryonic antigen (CEA) (1.26 ng/mL; normal 
＜5.0 ng/mL), carbohydrate antigen 19-9 (CA19-9) (6.8 
U/mL; normal ＜37.0 U/mL), and vitamin K absence or 
antagonist II (PIVKA-II) (15 mAU/mL; normal, ＜40.0 
mAU/mL), but elevated serum level of AFP (262.49 
IU/mL; normal, ＜7.0 IU/mL). Blood cell counts, blood 
coagulation tests, liver function tests, total bilirubin, amy-
lase, and lipase were all in normal range.
  Both contrast-enhanced (CE) pancreas CT and pan-
creaticobiliary magnetic resonance imaging (MRI) showed 
possibility of gastrointestinal stromal tumor (GIST) aris-
ing from the distal gastric antrum and greater curvature 
side with possible adhesion to the pancreas (Fig. 1A, B). 
A 7.5×5.8 cm well-defined mass was seen along the pan-
creatic groove. The mass was abutting the second duode-
nal wall and compressing the anterior surface of the pan-
creatic neck, causing narrowing of the main pancreatic 
duct. However, there was no definite evidence of invasion 
of pancreatic parenchyma. On positron emission tomog-
raphy, no other abnormal uptake in the rest of the im-
aged body was seen, except in the duodenum or in the 
pancreatic head, suggesting malignancy. Moreover, many 
multiple lymph node enlargements were seen on the less-
er omentum (Fig. 1D).
  Esophagogastroduodenoscopy showed extrinsic com-
pression of the gastric antrum and second portion of the 
duodenum but pathologic results showed no specific find-
ings, except chronic superficial gastritis with intestinal 
metaplasia (Fig. 1C). Therefore, endoscopic ultrasonogra-
phy-guided fine-needle aspiration biopsy was done on the 
primary mass revealing poorly differentiated adenocarcino-
ma.
  The patient underwent conventional Whipple operation 
(radical pancreaticoduodenectomy) with dissection of 
lymph nodes around the para-aorta, hepatoduodenal liga-
ment, and celiac axis.
  The external serosal surface of the mass was ragged 
and partly retracted, and its size was 8×9 cm including 
the necrotic center. The gastric mucosa showed ill-defined 
elevated lesion with central ulceration in greater curvature 
of the antrum measuring about 2×2 cm. On sections af-
ter fixation, the large necrotic solid portion was noted in 
the pancreas area with focal calcification (Fig. 2A). No 
metastasis was seen on the gallbladder, common bile duct 
and regional lymph nodes. However, prominent peri-tu-
moral lymphovascular permeation of tumor cells was 
seen. Microscopic examination revealed poorly differ-
entiated carcinoma showing variable architecture. The tu-
mor was composed of polygonal cells forming glands, 
papillae, and sheets. Tumor cells also showed vesicular 
nuclei and prominent nucleoli with abundant cytoplasm 
(Fig. 2B, C). Immunohistochemical stainings were per-
formed using primary antibodies of the following anti-
gens: cytokeratin (Fig. 3A), AFP (Fig. 3B), hepatocyte an-
tigen (Fig. 3C), chromogranin (Fig. 3D), synaptophysin 
(Fig. 3E), and alpha-1 antichymotrypsin (ACT) (Fig. 3F). 
100   Gut and Liver, Vol. 4, No. 1, March 2010
Fig. 2. (A) Cross-section of the pancreas after 24 hours formalin fixation. (B) Hematoxylin-eosin staining of carcinoma (original 
magnification, ×100). (C) Hematoxylin-eosin staining of carcinoma (×400).
Fig. 3. Immunohistochemical analysis for (A) cytokeratin, (B) AFP, (C) hepatocyte antigen, (D) chromogranin, (E) synaptophysin,
and (F) alpha-1 antichymotrypsin (×400).
Cytoplasmic positive reaction of carcinoma cells was 
strongly expressed for AFP, hepatocyte antigen, cytoker-
atin, and ACT, suggesting the hepatoid carcinoma and al-
so for chromogranin and synaptophysin, suggesting neu-
roendocrine carcinoma. Therefore, final diagnosis was ha-
patoid carcinoma combined with poorly differentiated 
neuroendocrine carcinoma arising from the pancreas and 
extending to the stomach and duodenum.
DISCUSSION
  The first hepatoid carcinoma of the pancreas was re-
ported in 1987 by Hruban et al. It was a case of peri-aci-
nar cell neoplasm with a solitary focus of hepatocellular 
differentiation. The clinical course of this patient demon-
strated very aggressive progress including both liver and 
lymph nodes metastasis with an overall survival of only 
2.75 months.4
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  AFP, a well-recognized oncofetal protein that appears in 
patients with malignant tumors such as HCC, germ-cell 
tumors, or some gastrointestinal tumors, has been found 
to be a sensitive serum marker in other extrahepatic hep-
atoid type tumors.5,6 In AFP-producing pancreatic tumors, 
serum AFP level is a useful marker for diagnosis and 
evaluation of therapeutic response and recurrence.7 
Immunohistochemical stains can be used for detection of 
hepatoid carcinoma. The more frequent positive proteins 
include keratin/cytokeratin cell adhesion molecule 5.2/AE, 
albumin, ACT, prealbumin, alpha-1-antitrypsin (AAT) 
protease inhibitor, and transferrin.2 In our case, strong 
expression of AFP and positive immunoreactivity for CEA 
and hepatocyte antigen strongly suggested the diagnosis 
of hepatoid tumor.
  Microscopically, diagnosis of hepatoid carcinoma was 
based on the following 2 criteria: (i) a mixture of tubular 
or papillary adenocarcinoma with sheet-like or trabecular 
proliferation of neoplastic cells within an AFP-producing 
carcinoma and (ii) the presence of cells with abundant 
eosinophilic cytoplasm and centrally located nuclei in the 
sheet-like or trabecular portions.8 However, our case 
showed cells of polygonal shape with glands, papillae, 
sheets, and abundant cytoplasm, which confused hepatoid 
carcinoma with poorly differentiated adenocarcinoma.
  Hepatocyte induction from the pancreas has been per-
formed in various animal models. Rao et al.9 inducted 
hepatocytes from the pancreas of rats maintained on a 
copper-deficient diet and followed by copper repletion. 
Therefore, a common progenitor cell in the pancreas from 
which hepatocytes and pancreatic cells could differentiate 
may exist. On the other hand, regenerating acinar cells or 
other differentiated cell types can transdifferentiate. 
Scarpelli et al.10 suggested that hepatocytes in the hamster 
pancreas were derived from acinar cells since trans-
formation had been apparently triggered by the carci-
nogen bis(oxopropyl) nitrosamine administered at the 
peak of pancreatic regeneration when the majority of aci-
nar cells were in S-phase. Makino et al.11 documented that 
pancreatic ductular epithelium in the hamster is the cell 
of origin. In addition, the fact that cells with features of 
both acinar/islet cells and hepatocytes were found in the 
pancreas of rats treated with hypolipidemic drugs could 
make the presumption that acinar/intermediate cells were 
precursor cells for hepatocytes.9 Paner et al.12 reviewed 5 
cases of hepatoid carcinoma of the pancreas. Three 
showed ductal cell carcinoma, 1 showed acinar cell carci-
noma, and 1 malignant glucagonoma. Therefore, hepatic 
differentiation could arise from any of the 3 main pancre-
atic cells (acinar, ductal, and islet cells). In our case, the 
tumor cells expressed both hepatoid and endocrine tumor 
cell features, suggesting islet cell origin. However, pancre-
atic cells might possess liver-specific genes normally in 
the repressed state that may be activated during the proc-
ess of carcinogenesis, expressing cells with a hepatic 
phenotype. This is supported by the close proximity and 
common embryonic origin (foregut endoderm) of the liver 
and pancreas.6,12 However, since hepatoid carcinoma can 
be developed in other germ-layer origins of organs, cel-
lular transdifferentiation is a more primordial explanation.
  The prognosis of hepatoid carcinoma of the pancreas 
could not be established due to the lack of cases. After a 
thorough review of the literature, only 9 cases of hep-
atoid carcinoma primarily arising from the pancreas have 
been reported to date. Although hepatoid carcinoma of 
the gastrointestinal tract generally shows poor prognosis, 
4 out of 9 cases did not have poor outcome; that is, after 
the initial diagnosis, 1 survived for 14 months, 1 for 48 
months, and the other 2 for 8.5 years and 28 
months.6,12-14 However, their biologic aggressiveness can 
be predicted through massive lymphatic and venous in-
vasion at the time of diagnosis, resulting in liver and 
lymph nodes metastasis. Moreover, florid proliferation 
within local veins mimics the behavior of HCC.1,4 The 
reason for poor prognosis of gastrointestinal tract-origi-
nated hepatoid carcinomas is not clearly understood. 
Nagai et al.15 reported that hepatoid carcinoma of the 
stomach had poorer prognosis regardless of producing 
AFP or not than AFP-producing nonhepatoid carcinoma. 
One possibility is that hepatoid carcinoma produces AAT 
and/or ACT as well as AFP. AAT and ACT have im-
munosuppressive and protease-inhibitory properties that 
enhance invasiveness.8 AFP also has suppressive effects 
on lymphocyte transformation.16 In addition, Koide et al.17 
have reported that AFP-producing gastric cancer has high 
proliferative activity, weak apoptosis, and rich neovas-
cularization.
  Hepatoid carcinoma is known to be resistant to 
chemotherapy. There was only 1 patient who was given 
chemotherapy with gemcitabine for 26 months because of 
newly developed liver metastasis at 12 months after 
operation. However, she underwent right lobectomy of 
the liver 39 months after the initial operation because of 
increase in tumor size.13
  In summary, we present a case of hepatoid carcinoma 
of the pancreas combined with neuroendocrine tumor. In 
reported examples in the literature, hepatoid carcinomas 
are often associated with early liver metastasis and short 
median survival although those arising as a component of 
endocrine tumors might fare slightly better. Therefore, it 
is important that hepatoid carcinoma should be consid-
ered as a possible malignant tumor of the pancreas.
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